Literature DB >> 9435201

Differential effects of intrathecally administered delta and mu opioid receptor agonists on formalin-evoked nociception and on the expression of Fos-like immunoreactivity in the spinal cord of the rat.

D L Hammond1, H Wang, N Nakashima, A I Basbaum.   

Abstract

This study examined the effects of intrathecally (i.t.) administered mu and delta opioid receptor agonists on the flinching behavior and the expression of Fos-like immunoreactivity (Fos-LI) in the spinal cord elicited by s.c. injection of 5% formalin in one hindpaw of the rat. Intrathecal pretreatment with either the delta-1 opioid receptor agonist [D-Pen2,5]enkephalin (DPDPE) or the delta-2 opioid receptor agonist [D-Ala2,Glu4]deltorphin (DELT) produced a dose-dependent inhibition of flinching behavior in phase 1 and phase 2 that was antagonized by coadministration of the delta-1 opioid receptor antagonist 7-benzylidinenaltrexone or the delta-2 opioid receptor antagonist Naltriben, respectively. Although i.t. pretreatment with 60 micrograms of DPDPE produced a small decrease in the numbers of Fos-LI neurons in laminae I, IIi and IIo, as well as laminae V and VI and laminae VII-X, i.t. pretreatment with 30 micrograms of DELT did not decrease the number of Fos-LI neurons in any region of the spinal cord. In contrast, i.t. pretreatment with an equieffective dose of the mu opioid receptor agonist [D-Ala2,NMePhe4,Gly-ol5]enkephalin (DAMGO) not only significantly decreased the number of flinches in phase 1 and phase 2, but also nearly completely prevented the expression of Fos-LI in all regions of the spinal cord. These effects were antagonized by pretreatment with the mu opioid receptor antagonist D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Phe-Thr-NH2. The efficacy of i.t. administered DAMGO suggests that a direct spinal action contributes to the inhibition of noxious stimulus-evoked Fos-LI in the spinal cord produced by systemically administered mu opioid receptor agonists such as morphine. The relative lack of effect of DPDPE or DELT suggests that delta opioid receptors do not modulate the early-immediate gene c-fos. Alternatively, because delta opioid receptor agonists inhibit synaptic transmission in the spinal cord by predominantly presynaptic mechanisms and do not hyperpolarize dorsal horn neurons, the excitatory inputs that persist in the presence of these agonists may be sufficient to activate the c-fos gene. Taken together, these results provide new evidence, at the level of a "third messenger," that the antinociception produced by i.t. administration of delta and mu opioid receptor agonists is mediated by different mechanisms.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9435201

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

1.  Electroacupuncture suppresses hyperalgesia and spinal Fos expression by activating the descending inhibitory system.

Authors:  Aihui Li; Yi Wang; Jiajia Xin; Lixing Lao; Ke Ren; Brian M Berman; Rui-Xin Zhang
Journal:  Brain Res       Date:  2007-10-22       Impact factor: 3.252

2.  Activation of spinal mu- and delta-opioid receptors potently inhibits substance P release induced by peripheral noxious stimuli.

Authors:  Hélène Beaudry; Dave Dubois; Louis Gendron
Journal:  J Neurosci       Date:  2011-09-14       Impact factor: 6.167

3.  Prolonged morphine treatment targets delta opioid receptors to neuronal plasma membranes and enhances delta-mediated antinociception.

Authors:  C M Cahill; A Morinville; M C Lee; J P Vincent; B Collier; A Beaudet
Journal:  J Neurosci       Date:  2001-10-01       Impact factor: 6.167

4.  Two delta opioid receptor subtypes are functional in single ventral tegmental area neurons, and can interact with the mu opioid receptor.

Authors:  Elyssa B Margolis; Wakako Fujita; Lakshmi A Devi; Howard L Fields
Journal:  Neuropharmacology       Date:  2017-06-21       Impact factor: 5.250

5.  Analgesic effect of intrathecally administered orexin-A in the rat formalin test and in the rat hot plate test.

Authors:  Tatsuo Yamamoto; Natsuko Nozaki-Taguchi; Tanemichi Chiba
Journal:  Br J Pharmacol       Date:  2002-09       Impact factor: 8.739

Review 6.  Modulation of pain transmission by G-protein-coupled receptors.

Authors:  Hui-Lin Pan; Zi-Zhen Wu; Hong-Yi Zhou; Shao-Rui Chen; Hong-Mei Zhang; De-Pei Li
Journal:  Pharmacol Ther       Date:  2007-09-22       Impact factor: 12.310

7.  Effects of intrathecal SNC80, a delta receptor ligand, on nociceptive threshold and dorsal horn substance p release.

Authors:  Milad Kouchek; Toshifumi Takasusuki; Tetsuji Terashima; Tony L Yaksh; Qinghao Xu
Journal:  J Pharmacol Exp Ther       Date:  2013-08-26       Impact factor: 4.030

8.  δ-opioid receptor and somatostatin receptor-4 heterodimerization: possible implications in modulation of pain associated signaling.

Authors:  Rishi K Somvanshi; Ujendra Kumar
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.